Literature DB >> 23358499

Influence of admixture components on CYP2C9*2 allele frequency in eight indigenous populations from Northwest Mexico.

M Sosa-Macías1, B P Lazalde-Ramos, C Galaviz-Hernández, H Rangel-Villalobos, J Salazar-Flores, V M Martínez-Sevilla, M L Martínez-Fierro, P Dorado, M L Wong, J Licinio, A LLerena.   

Abstract

We previously documented the lowest frequency of CYP2C9*2 in Mexican indigenous Tepehuanos followed by Mestizos and Mexican-Americans populations, suggesting a negative correlation between the CYP2C9*2 frequency and the degree of Asian ancestry in indigenous Americans. We determined the influence of ethnic admixture components on the CYP2C9 allele distribution in 505 Amerindian from eight indigenous populations through genotyping CYP2C9*2, *3 and *6 alleles by real-time PCR and molecular evaluation of ancestry. The frequencies for CYP2C9*2 were 0.026 in Seris and 0.057 in Mayos, being higher than in Asians (P<0.001). CYP2C9*3 was found in Tarahumaras (0.104), Mayos (0.091), Tepehuanos (0.075), Guarijíos (0.067), Huicholes (0.033) and Coras (0.037), with East Asians having lower frequencies than the former three groups (P<0.001). CYP2C9*6 was not found. The frequency of CYP2C9*2 was lower in Amerindians than in European populations, and higher than their Asian ancestors. The presence of this allele in ethnic groups in Mexico can be explained by European admixture.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23358499     DOI: 10.1038/tpj.2012.52

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  6 in total

1.  Prediction of CYP-mediated silybin A-losartan pharmacokinetic interactions using physiological based pharmacokinetic modeling.

Authors:  Ayesha Tanveer; Khalid Hussain; Hirra Tasneem; Iqra Arif; Memoona Rashid; Nasir Abbas; Rahat Shamim; Pervaiz A Shah; Nadeem Irfan Bukhari
Journal:  J Pharmacokinet Pharmacodyn       Date:  2022-01-21       Impact factor: 2.745

Review 2.  Pharmacogenomics of CYP2C9: Functional and Clinical Considerations.

Authors:  Ann K Daly; Allan E Rettie; Douglas M Fowler; John O Miners
Journal:  J Pers Med       Date:  2017-12-28

3.  The effect of CYP2C9*2, CYP2C9*3, and VKORC1-1639 G>A polymorphism in patients under warfarin therapy in city of Kermanshah.

Authors:  Zohreh Hosseinkhani; Mona Sadeghalvad; Fathemeh Norooznezhad; Reza Khodarahmi; Mohammad Fazilati; Azadeh Mahnam; Ali Fattahi; Kamran Mansouri
Journal:  Res Pharm Sci       Date:  2018-08

4.  Influence of Genetic Admixture Components on CYP3A5*3 Allele-Associated Hypertension in Amerindian Populations From Northwest Mexico.

Authors:  Carlos Galaviz-Hernández; Blanca P Lazalde-Ramos; Ismael Lares-Assef; Alejo Macías-Salas; Margarita A Ortega-Chavez; Héctor Rangel-Villalobos; Martha Sosa-Macías
Journal:  Front Pharmacol       Date:  2020-05-11       Impact factor: 5.810

5.  Genetic Diversity of Drug-Related Genes in Native Americans of the Brazilian Amazon.

Authors:  Marianne Rodrigues Fernandes; Juliana Carla Gomes Rodrigues; Olalla Maroñas; Ana Latorre-Pellicer; Raquel Cruz; João Farias Guerreiro; Rommel Mario Rodriguez Burbano; Paulo Pimentel de Assumpção; Andrea Ribeiro-Dos-Santos; Sidney Emanuel Batista Dos Santos; Angel Carracedo; Ney Pereira Carneiro Dos Santos
Journal:  Pharmgenomics Pers Med       Date:  2021-01-22

Review 6.  P450 Pharmacogenetics in Indigenous North American Populations.

Authors:  Lindsay M Henderson; Katrina G Claw; Erica L Woodahl; Renee F Robinson; Bert B Boyer; Wylie Burke; Kenneth E Thummel
Journal:  J Pers Med       Date:  2018-02-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.